CLUSTER filed Aug 11, 2026 at 16:05 ET
A cluster of insider sales at Twist Bioscience totaling $4.39M occurred within 9 days of a strong Q3 2026 earnings beat and raised guidance. The sales include CEO Emily Leproust ($435K), President/COO Patrick Finn ($246K), and Director Robert Chess ($2.04M, following option exercises). While the earnings report was bullish (revenue +23% YoY, guidance raised), the insider selling cluster, particularly the CEO's open-market sale, introduces a cautionary signal that partially offsets the positive fundamental momentum. The total sale value represents ~0.05% of the $8.2B market cap, which is below the 0.1% materiality threshold, suggesting these are routine liquidity-driven sales rather than informed bearish bets, especially given the stock's 94% analyst bullish consensus and strong historical performance.